biostudies-literatureUnknown42(10)Touzeau CJohnson &amp; Johnson<h4>Introduction</h4>Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM.<h4>Methods</h4>De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from theAdvances in therapy5023-5041https://www.ebi.ac.uk/biostudies/studies/S-EPMC12474644biostudies-literatureComparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.PMC12474644Touzeau CLee SZamagni EMina RYeh TMDytfeld DSidana SCorradini PNair SLeleu XSlaughter AZhao MPuig NDelforge MKhan AMSchecter JMLipe BLonardi CKarlin LHe JWeisel KChen DMendes JRoeloffzen WDhakal BLendvai NfalseComparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.<h4>Introduction</h4>Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM.<h4>Methods</h4>De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the2025-01-01T00:00:00Z2025 Oct2026-06-03T23:24:04.465Z2026-05-03T03:10:49.26ZS-EPMC124746444076819010.1007/s12325-025-03308-2